{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.619","value":"73.44"},{"groupId":"OG001","spread":"12.143","value":"68.92"},{"groupId":"OG002","spread":"28.349","value":"84.03"},{"groupId":"OG003","spread":"15.536","value":"61.34"},{"groupId":"OG004","spread":"20.296","value":"68.41"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"8"}],"units":"Participants"}],"title":"Baseline (Day 1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.750","value":"0.51"},{"groupId":"OG001","spread":"0.870","value":"0.34"},{"groupId":"OG002","spread":"0.929","value":"-0.43"},{"groupId":"OG003","spread":"1.794","value":"-0.22"},{"groupId":"OG004","spread":"0.695","value":"0.17"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"7"}],"units":"Participants"}],"title":"CFB to Cycle 2 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.624","value":"0.38"},{"groupId":"OG001","spread":"1.099","value":"0.52"},{"groupId":"OG002","spread":"0.495","value":"-0.15"},{"groupId":"OG003","spread":"1.040","value":"0.63"},{"groupId":"OG004","spread":"3.302","value":"-0.89"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"7"}],"units":"Participants"}],"title":"CFB to Cycle 3 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.863","value":"-0.80"},{"groupId":"OG001","spread":"0.173","value":"1.10"},{"groupId":"OG002","spread":"1.061","value":"-0.75"},{"groupId":"OG003","spread":"1.195","value":"1.18"},{"groupId":"OG004","spread":"2.967","value":"-0.17"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"6"}],"units":"Participants"}],"title":"CFB to Cycle 4 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.663","value":"0.07"},{"groupId":"OG001","spread":"0.656","value":"1.60"},{"comment":"Standard Deviation is not evaluable as only a single participant was analyzed.","groupId":"OG002","spread":"NA","value":"0.50"},{"groupId":"OG003","spread":"1.338","value":"1.43"},{"groupId":"OG004","spread":"4.575","value":"0.47"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"6"}],"units":"Participants"}],"title":"CFB to Cycle 5 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.889","value":"1.33"},{"groupId":"OG001","spread":"0.778","value":"1.45"},{"comment":"Standard Deviation is not evaluable as only a single participant was analyzed.","groupId":"OG002","spread":"NA","value":"-0.80"},{"groupId":"OG003","spread":"4.785","value":"1.88"},{"groupId":"OG004","spread":"3.664","value":"-2.88"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"5"}],"units":"Participants"}],"title":"CFB to Cycle 6 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.695","value":"0.13"},{"groupId":"OG001","spread":"0.212","value":"2.15"},{"comment":"Standard Deviation is not evaluable as only a single participant was analyzed.","groupId":"OG002","spread":"NA","value":"-1.20"},{"groupId":"OG003","spread":"1.344","value":"1.95"},{"groupId":"OG004","spread":"2.970","value":"-2.20"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"2"}],"units":"Participants"}],"title":"CFB to Cycle 7 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.843","value":"0.10"},{"groupId":"OG001","spread":"3.394","value":"-0.10"},{"comment":"Standard Deviation is not evaluable as only a single participant was analyzed.","groupId":"OG002","spread":"NA","value":"-1.40"},{"comment":"Standard Deviation is not evaluable as only a single participant was analyzed.","groupId":"OG003","spread":"NA","value":"3.00"},{"comment":"Standard Deviation is not evaluable as only a single participant was analyzed.","groupId":"OG004","spread":"NA","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"}],"units":"Participants"}],"title":"CFB to Cycle 8 Day 1"},{"categories":[{"measurements":[{"comment":"Standard Deviation is not evaluable as only a single participant was analyzed.","groupId":"OG000","spread":"NA","value":"5.00"},{"comment":"Standard Deviation is not evaluable as only a single participant was analyzed.","groupId":"OG001","spread":"NA","value":"2.50"},{"comment":"Standard Deviation is not evaluable as only a single participant was analyzed.","groupId":"OG002","spread":"NA","value":"-1.50"},{"comment":"Standard Deviation is not evaluable as only a single participant was analyzed.","groupId":"OG003","spread":"NA","value":"3.50"},{"comment":"Standard Deviation is not evaluable as only a single participant was analyzed.","groupId":"OG004","spread":"NA","value":"0.20"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"}],"units":"Participants"}],"title":"CFB to Cycle 9 Day 1"},{"categories":[{"measurements":[{"comment":"Standard Deviation is not evaluable as only a single participant was analyzed.","groupId":"OG000","spread":"NA","value":"3.30"},{"comment":"Standard Deviation is not evaluable as only a single participant was analyzed.","groupId":"OG001","spread":"NA","value":"2.60"},{"comment":"Standard Deviation is not evaluable as only a single participant was analyzed.","groupId":"OG002","spread":"NA","value":"-1.60"},{"comment":"Standard Deviation is not evaluable as only a single participant was analyzed.","groupId":"OG003","spread":"NA","value":"3.60"},{"comment":"Standard Deviation is not evaluable as only a single participant was analyzed.","groupId":"OG004","spread":"NA","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"}],"units":"Participants"}],"title":"CFB to Cycle 10 Day 1"},{"categories":[{"measurements":[{"comment":"Standard Deviation is not evaluable as only a single participant was analyzed.","groupId":"OG000","spread":"NA","value":"3.40"},{"comment":"Standard Deviation is not evaluable as only a single participant was analyzed.","groupId":"OG001","spread":"NA","value":"2.50"},{"comment":"Standard Deviation is not evaluable as only a single participant was analyzed.","groupId":"OG002","spread":"NA","value":"-1.70"},{"comment":"Standard Deviation is not evaluable as only a single participant was analyzed.","groupId":"OG003","spread":"NA","value":"3.00"},{"comment":"Standard Deviation is not evaluable as only a single participant was analyzed.","groupId":"OG004","spread":"NA","value":"-0.40"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"}],"units":"Participants"}],"title":"CFB to Cycle 11 Day 1"},{"categories":[{"measurements":[{"comment":"Standard Deviation is not evaluable as only a single participant was analyzed.","groupId":"OG000","spread":"NA","value":"3.30"},{"comment":"Standard Deviation is not evaluable as only a single participant was analyzed.","groupId":"OG001","spread":"NA","value":"2.30"},{"comment":"Standard Deviation is not evaluable as only a single participant was analyzed.","groupId":"OG002","spread":"NA","value":"-1.70"},{"comment":"Standard Deviation is not evaluable as only a single participant was analyzed.","groupId":"OG003","spread":"NA","value":"4.50"},{"comment":"Standard Deviation is not evaluable as only a single participant was analyzed.","groupId":"OG004","spread":"NA","value":"-0.40"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"}],"units":"Participants"}],"title":"CFB to Cycle 12 Day 1"},{"categories":[{"measurements":[{"comment":"Standard Deviation is not evaluable as only a single participant was analyzed.","groupId":"OG000","spread":"NA","value":"2.90"},{"comment":"Standard Deviation is not evaluable as only a single participant was analyzed.","groupId":"OG001","spread":"NA","value":"2.40"},{"comment":"Standard Deviation is not evaluable as only a single participant was analyzed.","groupId":"OG002","spread":"NA","value":"-1.80"},{"comment":"Standard Deviation is not evaluable as only a single participant was analyzed.","groupId":"OG003","spread":"NA","value":"4.80"},{"comment":"Standard Deviation is not evaluable as only a single participant was analyzed.","groupId":"OG004","spread":"NA","value":"-0.40"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"}],"units":"Participants"}],"title":"CFB to Cycle 13 Day 1"},{"categories":[{"measurements":[{"comment":"Standard Deviation is not evaluable as only a single participant was analyzed.","groupId":"OG000","spread":"NA","value":"5.50"},{"comment":"Standard Deviation is not evaluable as only a single participant was analyzed.","groupId":"OG001","spread":"NA","value":"2.50"},{"comment":"Standard Deviation is not evaluable as only a single participant was analyzed.","groupId":"OG002","spread":"NA","value":"-1.60"},{"comment":"Standard Deviation is not evaluable as only a single participant was analyzed.","groupId":"OG003","spread":"NA","value":"3.00"},{"comment":"Standard Deviation is not evaluable as only a single participant was analyzed.","groupId":"OG004","spread":"NA","value":"-0.70"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"}],"units":"Participants"}],"title":"CFB to Cycle 14 Day 1"},{"categories":[{"measurements":[{"comment":"Standard Deviation is not evaluable as only a single participant was analyzed.","groupId":"OG000","spread":"NA","value":"6.50"},{"comment":"Standard Deviation is not evaluable as only a single participant was analyzed.","groupId":"OG001","spread":"NA","value":"2.40"},{"comment":"Standard Deviation is not evaluable as only a single participant was analyzed.","groupId":"OG002","spread":"NA","value":"-1.40"},{"comment":"Standard Deviation is not evaluable as only a single participant was analyzed.","groupId":"OG003","spread":"NA","value":"2.00"},{"comment":"Standard Deviation is not evaluable as only a single participant was analyzed.","groupId":"OG004","spread":"NA","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"}],"units":"Participants"}],"title":"CFB to Cycle 15 Day 1"},{"categories":[{"measurements":[{"comment":"Standard Deviation is not evaluable as only a single participant was analyzed.","groupId":"OG000","spread":"NA","value":"4.80"},{"comment":"Standard Deviation is not evaluable as only a single participant was analyzed.","groupId":"OG001","spread":"NA","value":"2.70"},{"comment":"Standard Deviation is not evaluable as only a single participant was analyzed.","groupId":"OG002","spread":"NA","value":"-1.50"},{"comment":"Standard Deviation is not evaluable as only a single participant was analyzed.","groupId":"OG003","spread":"NA","value":"1.30"},{"comment":"Standard Deviation is not evaluable as only a single participant was analyzed.","groupId":"OG004","spread":"NA","value":"0.20"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"}],"units":"Participants"}],"title":"CFB to Cycle 16 Day 1"},{"categories":[{"measurements":[{"comment":"Standard Deviation is not evaluable as only a single participant was analyzed.","groupId":"OG000","spread":"NA","value":"3.00"},{"comment":"Standard Deviation is not evaluable as only a single participant was analyzed.","groupId":"OG001","spread":"NA","value":"2.10"},{"comment":"Standard Deviation is not evaluable as only a single participant was analyzed.","groupId":"OG002","spread":"NA","value":"-1.60"},{"comment":"Standard Deviation is not evaluable as only a single participant was analyzed.","groupId":"OG003","spread":"NA","value":"1.60"},{"comment":"Standard Deviation is not evaluable as only a single participant was analyzed.","groupId":"OG004","spread":"NA","value":"-0.20"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"}],"units":"Participants"}],"title":"CFB to Cycle 17 Day 1"},{"categories":[{"measurements":[{"comment":"Standard Deviation is not evaluable as only a single participant was analyzed.","groupId":"OG000","spread":"NA","value":"2.00"},{"comment":"Standard Deviation is not evaluable as only a single participant was analyzed.","groupId":"OG001","spread":"NA","value":"2.00"},{"comment":"Standard Deviation is not evaluable as only a single participant was analyzed.","groupId":"OG002","spread":"NA","value":"-1.80"},{"comment":"Standard Deviation is not evaluable as only a single participant was analyzed.","groupId":"OG003","spread":"NA","value":"1.00"},{"comment":"Standard Deviation is not evaluable as only a single participant was analyzed.","groupId":"OG004","spread":"NA","value":"0.30"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"}],"units":"Participants"}],"title":"CFB to Cycle 18 Day 1"},{"categories":[{"measurements":[{"comment":"Standard Deviation is not evaluable as only a single participant was analyzed.","groupId":"OG000","spread":"NA","value":"1.60"},{"comment":"Standard Deviation is not evaluable as only a single participant was analyzed.","groupId":"OG001","spread":"NA","value":"2.30"},{"comment":"Standard Deviation is not evaluable as only a single participant was analyzed.","groupId":"OG002","spread":"NA","value":"-1.70"},{"comment":"Standard Deviation is not evaluable as only a single participant was analyzed.","groupId":"OG003","spread":"NA","value":"0.70"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"CFB to Cycle 19 Day 1"},{"categories":[{"measurements":[{"comment":"Standard Deviation is not evaluable as only a single participant was analyzed.","groupId":"OG000","spread":"NA","value":"0.70"},{"comment":"Standard Deviation is not evaluable as only a single participant was analyzed.","groupId":"OG003","spread":"NA","value":"0.90"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"CFB to Cycle 20 Day 1"},{"categories":[{"measurements":[{"comment":"Standard Deviation is not evaluable as only a single participant was analyzed.","groupId":"OG000","spread":"NA","value":"1.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"CFB to Cycle 21 Day 1"},{"categories":[{"measurements":[{"comment":"Standard Deviation is not evaluable as only a single participant was analyzed.","groupId":"OG000","spread":"NA","value":"1.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"CFB to Cycle 22 Day 1"},{"categories":[{"measurements":[{"comment":"Standard Deviation is not evaluable as only a single participant was analyzed.","groupId":"OG000","spread":"NA","value":"2.80"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"CFB to Cycle 23 Day 1"},{"categories":[{"measurements":[{"comment":"Standard Deviation is not evaluable as only a single participant was analyzed.","groupId":"OG001","spread":"NA","value":"2.50"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"CFB to Week 07"},{"categories":[{"measurements":[{"comment":"Standard Deviation is not evaluable as only a single participant was analyzed.","groupId":"OG001","spread":"NA","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"CFB to Week 10"},{"categories":[{"measurements":[{"comment":"Standard Deviation is not evaluable as only a single participant was analyzed.","groupId":"OG001","spread":"NA","value":"-3.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"CFB to Week 13"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.886","value":"-1.38"},{"groupId":"OG001","spread":"2.856","value":"0.47"},{"comment":"Standard Deviation is not evaluable as only a single participant was analyzed.","groupId":"OG002","spread":"NA","value":"0.00"},{"groupId":"OG003","spread":"1.273","value":"-0.80"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"CFB to End of Treatment (Up to 236 weeks)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"8"}],"units":"Participants"}],"description":"Physical examination parameter weight was assessed. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline","dispersionType":"Standard Deviation","groups":[{"description":"Participants with Relapsed/Refractory Multiple Myeloma (RRMM) who have had at least 3 lines of prior treatment (or at least 2 lines of prior treatment if ineligible for autologous stem cell transplantation) and normal/mildly impaired renal function received intravenous (IV) infusion of 2.5 milligram (mg)/kilogram (kg) belantamab mafodotin for 30 minutes on Day 1 of every 21-day Cycle until disease progression, withdrawal of consent, withdrawal due to adverse event (AE), lost to follow-up, death, whichever occurs first.","id":"OG000","title":"Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)"},{"description":"Participants with RRMM who have had at least 3 lines of prior treatment (or at least 2 lines of prior treatment if ineligible for autologous stem cell transplantation) and severe renal impairment renal function received IV infusion of 2.5 mg/kg belantamab mafodotin for 30 minutes on Day 1 of every 21-day Cycle until disease progression, withdrawal of consent, withdrawal due to AE, lost to follow-up, death, whichever occurs first.","id":"OG001","title":"Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)"},{"description":"Participants with RRMM who have had at least 3 lines of prior treatment (or at least 2 lines of prior treatment if ineligible for autologous stem cell transplantation) and other renal impairment renal function received IV infusion of 2.5 mg/kg belantamab mafodotin for 30 minutes on Day 1 of every 21-day Cycle until disease progression, withdrawal of consent, withdrawal due to AE, lost to follow-up, death, whichever occurs first.","id":"OG002","title":"Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function)"},{"description":"Participants with RRMM who have had at least 3 lines of prior treatment (or at least 2 lines of prior treatment if ineligible for autologous stem cell transplantation) and end stage renal disease (ESRD) (not on hemodialysis) received IV infusion of 2.5 mg/kg belantamab mafodotin for 30 minutes on Day 1 of every 21-day Cycle until disease progression, withdrawal of consent, withdrawal due to AE, lost to follow-up, death, whichever occurs first.","id":"OG003","title":"Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)"},{"description":"Participants with RRMM who have had at least 3 lines of prior treatment (or at least 2 lines of prior treatment if ineligible for autologous stem cell transplantation) and ESRD (on hemodialysis) received IV infusion of 2.5 mg/kg belantamab mafodotin for 30 minutes on Day 1 of every 21-day Cycle until disease progression, withdrawal of consent, withdrawal due to AE, lost to follow-up, death, whichever occurs first.","id":"OG004","title":"Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)"}],"paramType":"MEAN","populationDescription":"Safety population. Only those participants who were measured and analyzed (i.e., contributed to data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified timepoints. The \"0\" participants analyzed represents that data was not collected or available for analysis at that particular time point for the respective Arms/Groups.","reportingStatus":"POSTED","timeFrame":"Baseline (Day 1) and up to approx. 236 weeks","title":"Part 1 and Part 2: Change From Baseline (CFB) in Weight","type":"SECONDARY","unitOfMeasure":"Kilogram (Kg)"}